Comparison of Radiolableled Somatostatin Analogues and (131) I-MIBG Treatment for the Management of Patients with Metastatic/Progressive Phaeochromocytomas and Paragangliomas

#941

Introduction: Radionuclide therapy has been used to treat patients with progressive/metastatic paragangliomas (PGGs) and pheochromocytomas (PCCs). To date, there is no study comparing (131)I-MIBG and peptide receptor radionuclide treatment (PRRT) in those patients.

Aim(s): To compare the effectiveness of those modalities in progressive PCCs and PGGs.

Materials and methods: All patients had progressive tumors, despite previous treatments. Overall survival (OS), progression-free survival (PFS), event-free survival (EFS) and response to treatment were calculated. Renal and hematological toxicity were documented.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Nastos K, Toumpanakis C, Cheung V, Navalkissoor S, Quigley A,

Keywords: paraganglioma, pheochromocytoma, (131)I-MIBG, PRRT,